Study guide
20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
Key Takeaways Explain This Topic AI
The PADIS guidelines prioritize analgosedation and light sedation (RASS − 1 to 0 -1\text{ to } 0 − 1 to 0 ) paired with daily sedation interruption and spontaneous breathing trials (ABCDEF bundle).
Hypoactive delirium accounts for 50 − 60 % 50-60\% 50 − 60% of ICU delirium cases, remains frequently under-recognized, and carries a significantly worse long-term cognitive and survival prognosis than hyperactive delirium.
The Rapid Shallow Breathing Index ( R S B I = f / V T RSBI = f / V_T RSB I = f / V T ) evaluates weaning readiness; an R S B I < 105 breaths/min/L RSBI < 105\text{ breaths/min/L} RSB I < 105 breaths/min/L strongly predicts extubation success, while > 105 >105 > 105 predicts failure.
Brain death determination requires an established irreversible cause and exclusion of confounders (temperature threshold set nationally, e.g. ≥ 36 °C \ge 36\text{°C} ≥ 36 °C in World Brain Death Project criteria), followed by absent brainstem reflexes and a positive apnea test ( P a CO 2 ≥ 60 mmHg P_a\text{CO}_2 \ge 60\text{ mmHg} P a CO 2 ≥ 60 mmHg with p H < 7.30 pH < 7.30 p H < 7.30 under World Brain Death Project criteria).
Last updated: October 2026
20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
Critical care management encompasses the continuum from patient comfort and neurocognitive protection to liberation from mechanical ventilation and the rigorous, protocolized determination of death by neurological criteria. Candidates for the EDAIC Part I examination must possess in-depth knowledge of sedation pharmacology, delirium screening algorithms, extubation predictors, and the legal-medical prerequisites of brain death.
The PADIS Clinical Practice Guidelines: Analgosedation
The Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) guidelines endorse an analgesia-first ("analgosedation") model of critical care sedation.
1. Analgesia-First Model
Pain is the primary driver of physiological stress, tachycardia, hypertension, ventilator fighting, sleep disruption, and post-traumatic stress disorder in critically ill patients.
Analgosedation prioritizes assessing and treating pain with intravenous opioids (e.g., remifentanil, fentanyl, hydromorphone) before administering hypnotic sedatives. In many postoperative and mechanically ventilated patients, adequate analgesia eliminates the requirement for sedative infusions entirely.
Pain Assessment: Validated behavioral scoring systems are required for non-verbal, mechanically ventilated patients: the Behavioral Pain Scale (BPS) (scored 3–12 based on facial expression, upper limb movements, and ventilator compliance) or the Critical-Care Pain Observation Tool (CPOT) (scored 0–8).
2. Light Sedation Targets
Clinical trials demonstrate that light sedation (patient is responsive to verbal commands, able to maintain eye contact, and can participate in care) is associated with shorter duration of mechanical ventilation, reduced ICU length of stay, and lower rates of tracheostomy compared to deep sedation.
Standardized Sedation Scales:
Richmond Agitation-Sedation Scale (RASS): Target score of − 1 (drowsy) -1\text{ (drowsy)} − 1 (drowsy) to 0 (alert and calm) 0\text{ (alert and calm)} 0 (alert and calm) .
Riker Sedation-Agitation Scale (SAS): Target score of 3 to 4 3\text{ to }4 3 to 4 .
3. Daily Sedation Interruption (DSI) and the ABCDEF Bundle
Daily Sedation Interruption (Spontaneous Awakening Trials / SAT): Daily cessation or reduction of sedative infusions until the patient is awake and able to execute simple commands (or develops marked agitation/respiratory distress). Paired with Spontaneous Breathing Trials (SBT), SAT significantly accelerates ventilator liberation.
The ABCDEF Interprofessional Bundle:
- A: A ssess, prevent, and manage pain
- B: B oth Spontaneous Awakening Trials (SAT) and Spontaneous Breathing Trials (SBT)
- C: C hoice of analgesia and sedation (avoiding benzodiazepines)
- D: D elirium: assess, prevent, and manage
- E: E arly mobility and exercise
- F: F amily engagement and empowerment
- Pharmacology of Common ICU Sedative Agents
Pharmacological Agent Mechanism of Action Clinical Advantages Adverse Effects and Toxicity Profile
Propofol GABA A \text{GABA}_A GABA A receptor agonist; sodium channel blocker Rapid onset ( 30 − 60 s 30-60\text{ s} 30 − 60 s ), ultra-short context-sensitive half-time; rapid emergence; reduces cerebral metabolic rate ( C M R O 2 CMRO_2 CMR O 2 ) and ICP Dose-dependent hypotension (vasodilation and myocardial depression), hypertriglyceridemia, acute pancreatitis. Propofol Infusion Syndrome (PRIS): High dose ( > 4 − 5 mg/kg/hour >4-5\text{ mg/kg/hour} > 4 − 5 mg/kg/hour or > 67 − 83 mcg/kg/min >67-83\text{ mcg/kg/min} > 67 − 83 mcg/kg/min ) for > 48 hours >48\text{ hours} > 48 hours ; characterized by severe metabolic acidosis, rhabdomyolysis, hyperkalemia, hepatomegaly, acute renal failure, and refractory bradyarrhythmias/asystole.
Dexmedetomidine Highly selective centrally acting α 2 \alpha_2 α 2 -adrenoceptor agonist ( α 2 : α 1 \alpha_2:\alpha_1 α 2 : α 1 ratio 1620 : 1 1620:1 1620 : 1 ) Acts on the locus coeruleus in the pons to induce a state resembling non-REM stage 2 sleep ("cooperative" sedation); preserves spontaneous ventilatory drive ; opioid-sparing; significantly reduces delirium incidence and duration Dose-dependent bradycardia and hypotension (via peripheral sympatholysis and presynaptic α 2 \alpha_2 α 2 stimulation). Lacks deep amnesic properties.
Benzodiazepines (Midazolam, Lorazepam) GABA A \text{GABA}_A GABA A receptor positive allosteric modulators Amnesia, anxiolysis, anticonvulsant activity; hemodynamic stability compared to propofol Independent risk factor for delirium ; prolonged emergence, cognitive impairment; active metabolites accumulate in renal/hepatic dysfunction (e.g., 1-hydroxymidazolam). Guidelines recommend avoiding benzodiazepines for routine ICU sedation , reserving them strictly for alcohol withdrawal, status epilepticus, or deep neuromuscular blockade.
Ketamine Non-competitive NMDA receptor antagonist; opioid/monoaminergic reuptake inhibition Potent analgesic and amnesic properties; preserves airway reflexes and functional residual capacity; bronchodilation ; maintains hemodynamic stability via sympathetic stimulation Emergence delirium, hallucinations, hypersecretion, sympathetic hyperactivation (tachycardia, hypertension), potential elevation of C M R O 2 CMRO_2 CMR O 2 in unprotected closed head injuries.
Delirium in the Intensive Care Unit: Subtypes and CAM-ICU
Delirium is an acute, fluctuating disturbance in attention, awareness, and baseline cognition. It affects up to 80 % 80\% 80% of mechanically ventilated ICU patients and independently predicts prolonged hospitalization, long-term cognitive impairment, and increased 6-month mortality.
1. Clinical Subtypes of Delirium
Hypoactive Delirium ( 50 − 60 % 50-60\% 50 − 60% of cases): Characterized by lethargy, psychomotor slowing, apathy, and decreased responsiveness. Frequently misdiagnosed as depression, fatigue, or over-sedation ("quiet delirium"). Carries the highest hospital mortality and poorest long-term neurocognitive prognosis.
Hyperactive Delirium ( < 10 − 15 % <10-15\% < 10 − 15% of cases): Characterized by psychomotor agitation, combativeness, hallucinations, emotional lability, and dangerous pulling at endotracheal tubes and vascular catheters.
Mixed Delirium ( 30 − 40 % 30-40\% 30 − 40% of cases): Demonstrates fluctuations between hyperactive and hypoactive states over a 24-hour cycle.
2. Confusion Assessment Method for the ICU (CAM-ICU)
The CAM-ICU is the standard bedside screening tool. It can only be assessed if the patient is sufficiently arousable to verbal stimulation (i.e., RASS score ≥ − 3 \ge -3 ≥ − 3 ). If the patient is deeply sedated or comatose (RASS − 4 -4 − 4 or − 5 -5 − 5 ), delirium assessment is deferred. CAM-ICU Diagnostic Algorithm (Evaluated when RASS >= -3):
- [Feature 1: Acute Onset or Fluctuating Course] ──(Must be Present)──┐
- │
- [Feature 2: Inattention (Letter Test)] ─────────(Must be Present)──┼──> DELIRIUM POSITIVE
- │ (Requires 1 + 2 and
- ┌───────────────────────────────────────────────────────────┘ EITHER 3 or 4)
- ▼
- [Feature 3: Altered Level of Consciousness (Current RASS != 0)]
- OR
- [Feature 4: Disorganized Thinking (> 1 error on logic questions)]
Feature 1: Acute Onset or Fluctuating Course: Evidence of an acute change in mental status from baseline, OR fluctuations in mental status over the preceding 24 hours (e.g., fluctuating RASS scores).
Feature 2: Inattention: Assessed via the auditory Attention Screening Examination (ASE): the clinician reads 10 letters ("S-A-V-E-A-H-A-A-R-T") and instructs the patient to squeeze their hand on the letter "A". More than 2 errors (squeezing on a non-A letter or failing to squeeze on "A") indicates inattention.
Feature 3: Altered Level of Consciousness: Evaluated simply by the patient's current sedation level. Any current RASS score other than 0 (alert and calm) 0\text{ (alert and calm)} 0 (alert and calm) (e.g., + 1 +1 + 1 , + 2 +2 + 2 , − 1 -1 − 1 , − 2 -2 − 2 ) constitutes a positive Feature 3.
Feature 4: Disorganized Thinking: Evaluated if Feature 3 is negative (current RASS is 0). The patient is asked 4 simple logic questions (e.g., "Will a stone float on water?", "Are there fish in the sea?", "Does one pound weigh more than two pounds?", "Can you use a hammer to pound a nail?") and instructed to follow a command ("Hold up this many fingers"). More than 1 error indicates disorganized thinking.
Diagnostic Rule: Delirium is confirmed if Feature 1 AND Feature 2 are present, PLUS EITHER Feature 3 OR Feature 4.
3. Prevention and Management
Non-Pharmacological Bundle (Primary Therapy): Early physical therapy and mobilization, promotion of normal sleep architecture (minimizing nighttime noise, clustering nursing care, keeping room lights on during the day and off at night), frequent cognitive reorientation, providing sensory aids (eyeglasses, hearing aids), early removal of physical restraints and invasive catheters.
Pharmacological Recommendations: PADIS guidelines explicitly advise against the routine prophylactic administration of antipsychotics (haloperidol, quetiapine, olanzapine) to prevent or treat delirium. Antipsychotics should be reserved strictly for short-term control of severe agitation that threatens patient or staff safety.
Liberation from Mechanical Ventilation and Weaning Predictors
Weaning is the process of gradually transitioning a patient from full mechanical ventilatory support to unassisted spontaneous breathing and extubation.
1. Readiness Criteria for a Spontaneous Breathing Trial (SBT)
Before initiating an SBT, the patient must fulfill objective physiological readiness criteria:
Resolution or Substantial Improvement: The underlying acute respiratory pathology that necessitated intubation has stabilized or improved.
Adequate Oxygenation: P a O 2 / F i O 2 ≥ 150 − 200 mmHg P_a\text{O}_2/F_i\text{O}_2 \ge 150-200\text{ mmHg} P a O 2 / F i O 2 ≥ 150 − 200 mmHg on PEEP ≤ 5 − 8 cm H 2 O \text{PEEP} \le 5-8\text{ cm}\text{H}_2\text{O} PEEP ≤ 5 − 8 cm H 2 O and F i O 2 ≤ 0.40 − 0.50 F_i\text{O}_2 \le 0.40-0.50 F i O 2 ≤ 0.40 − 0.50 , with arterial p H ≥ 7.30 pH \ge 7.30 p H ≥ 7.30 .
Hemodynamic Stability: Absence of active myocardial ischemia; low or no vasopressor support (e.g., dopamine < 5 mcg/kg/min <5\text{ mcg/kg/min} < 5 mcg/kg/min or norepinephrine < 0.05 − 0.1 mcg/kg/min <0.05-0.1\text{ mcg/kg/min} < 0.05 − 0.1 mcg/kg/min ).
Neurological and Airway Adequacy: Patient is arousable, cooperative, able to follow commands (GCS ≥ 8 − 9 \ge 8-9 ≥ 8 − 9 ), has strong protective airway reflexes (vigorous cough on endotracheal suctioning), and manageable volume/viscosity of tracheobronchial secretions.
2. The Spontaneous Breathing Trial (SBT)
Technique: Performed for 30 to 120 minutes 30\text{ to }120\text{ minutes} 30 to 120 minutes using either a T-piece circuit or low-level pressure support ventilation (PSV of ≤ 5 − 7 cm H 2 O \le 5-7\text{ cm}\text{H}_2\text{O} ≤ 5 − 7 cm H 2 O with PEEP 0 − 5 cm H 2 O 0-5\text{ cm}\text{H}_2\text{O} 0 − 5 cm H 2 O ).
Failure Criteria: Respiratory rate > 35 breaths/min >35\text{ breaths/min} > 35 breaths/min or < 8 breaths/min <8\text{ breaths/min} < 8 breaths/min ; S p O 2 < 90 % S_p\text{O}_2 < 90\% S p O 2 < 90% ; heart rate > 140 bpm >140\text{ bpm} > 140 bpm or > 20 % change >20\%\text{ change} > 20% change from baseline; systolic blood pressure > 180 mmHg >180\text{ mmHg} > 180 mmHg or < 90 mmHg <90\text{ mmHg} < 90 mmHg ; development of diaphoresis, intercostal indrawing, thoracoabdominal paradox, or new cardiac dysrhythmias.
3. The Rapid Shallow Breathing Index (RSBI / Yang-Tobin Index)
The RSBI is the most widely validated objective physiological predictor of extubation success:
RSBI = f V T \text{RSBI} = \frac{f}{V_T} RSBI = V T f
Where f f f is the spontaneous respiratory rate in breaths per minute, and V T V_T V T is the spontaneous tidal volume in liters , measured during 1 minute 1\text{ minute} 1 minute of unassisted breathing through a T-piece or a spirometer connected to the endotracheal tube.
RSBI < 105 breaths/min/L \text{RSBI} < 105\text{ breaths/min/L} RSBI < 105 breaths/min/L : Predicts successful weaning and extubation (high sensitivity ≈ 97 % \approx 97\% ≈ 97% , moderate specificity).
RSBI > 105 breaths/min/L \text{RSBI} > 105\text{ breaths/min/L} RSBI > 105 breaths/min/L : Strongly predictive of weaning failure. Reflects rapid, shallow ventilatory mechanics driven by diaphragmatic fatigue, decreased respiratory compliance, or elevated dead space.
4. Cuff-Leak Test and Post-Extubation Stridor
Cuff-Leak Test: Deflating the endotracheal tube cuff during volume-controlled ventilation to assess for peritubal air leak around the tube. An absolute cuff-leak volume < 110 − 130 mL <110-130\text{ mL} < 110 − 130 mL (or < 15 − 24 % <15-24\% < 15 − 24% of delivered tidal volume) indicates severe laryngeal edema and high risk of post-extubation stridor and re-intubation.
Prevention: In high-risk patients with a failed cuff-leak test, administering intravenous corticosteroids (e.g., methylprednisolone 20 − 40 mg 20-40\text{ mg} 20 − 40 mg IV every 4–6 hours) initiated at least 4 to 6 hours 4\text{ to }6\text{ hours} 4 to 6 hours prior to extubation significantly reduces laryngeal edema and post-extubation stridor.
Determination of Death by Neurological Criteria (Brain Death)
Brain death represents the complete, irreversible cessation of all functions of the entire brain, including the brainstem. The determination is fundamentally a clinical diagnosis that requires strict adherence to standardized legal-medical prerequisites.
1. Mandatory Prerequisites (Confounders Must Be Excluded)
Prior to initiating brainstem reflex testing, the following conditions must be fulfilled:
Established, Irreversible Brain Damage: An established, documented catastrophic structural or anoxic etiology sufficient to account for brain death (e.g., massive intraparenchymal hemorrhage, severe traumatic brain injury, confirmed anoxic encephalopathy post-cardiac arrest).
Adequate Core Temperature: The threshold varies by national code: ≥ 36 °C \ge 36\text{°C} ≥ 36 °C in the World Brain Death Project (2020) and the 2023 US adult and paediatric guideline, but > 34 °C > 34\text{°C} > 34 °C in the UK Academy of Medical Royal Colleges code (2008). Severe hypothermia suppresses neuronal conduction and abolishes brainstem reflexes.
Hemodynamic Stability: Systolic blood pressure must be ≥ 100 mmHg \ge 100\text{ mmHg} ≥ 100 mmHg or mean arterial pressure ≥ 60 − 65 mmHg \ge 60-65\text{ mmHg} ≥ 60 − 65 mmHg . Vasopressors or inotropes may be titrated to achieve this threshold.
Exclusion of Metabolic and Endocrine Confounders: Severe electrolyte abnormalities (e.g., profound hyponatremia/hypernatremia), profound hypoglycemia, severe acid-base disturbances, hepatic failure, uremic encephalopathy, severe hypothyroidism (myxedema coma), and adrenal crisis must be excluded or corrected.
Exclusion of Neuromuscular Blockade and CNS Depressants:
Absence of residual neuromuscular blockade confirmed by Train-of-Four (TOF) peripheral nerve stimulation demonstrating 4 / 4 4/4 4/4 robust twitches .
Complete clearance of all central depressant drugs (sedatives, opioids, barbiturates, anticholinergics). Clinicians must confirm either negative toxicological drug levels or allow the passage of at least 5 elimination half-lives 5\text{ elimination half-lives} 5 elimination half-lives , calculated taking into account hypothermia-induced enzyme impairment, hepatic dysfunction, or renal failure.
2. Clinical Brainstem Reflex Examination (Must Be Completely Absent)
Brainstem Reflex Tested Cranial Nerves Involved Clinical Testing Method and Confirmation of Absent Response
Pupillary Light Reflex CN II (Afferent); CN III (Efferent) Absence of pupillary constriction to bright light in both eyes. Pupils are typically fixed and dilated ( > 4 mm >4\text{ mm} > 4 mm ) or mid-position ( 4 − 6 mm 4-6\text{ mm} 4 − 6 mm ).
Corneal Reflex CN V (Afferent, ophthalmic); CN VII (Efferent) Absence of eyelid blink when gently touching the lateral corneal limbus with a sterile cotton swab or saline drops.
Oculocephalic Reflex ("Doll's Eyes") CN III, VI, VIII Tested only if cervical spine integrity is cleared. Rapid horizontal and vertical head rotation results in no ocular movement; the eyes remain fixed in their orbits relative to the head.
Vestibulo-Ocular Reflex (Cold Caloric Test) CN VIII (Afferent); CN III, VI (Efferent) Elevate head of bed to 30 ° 30\text{°} 30 ° . Otoscopic confirmation of patent external auditory canal and intact tympanic membrane. Irrigate canal with 50 mL 50\text{ mL} 50 mL of ice-cold water over 1 minute 1\text{ minute} 1 minute . Observe eyes for 1 − 2 minutes 1-2\text{ minutes} 1 − 2 minutes . Positive for brain death: complete absence of all conjugate or disconjugate ocular movement.
Gag Reflex CN IX (Afferent); CN X (Efferent) Absence of pharyngeal contraction when touching the posterior pharyngeal wall bilaterally with a tongue blade or suction catheter.
Cough / Tracheal Reflex CN X (Afferent & Efferent) Absence of cough response when passing an endotracheal suction catheter deeply down to the level of the carina.
Motor Response to Pain Brainstem / Cranial Nerves Absence of any motor response in the cranial nerve distribution (grimacing, facial movement) to deep noxious stimulation applied to the supraorbital notch, temporomandibular joint, or sternum.
Spinal Reflexes vs Brain Death: Spinally mediated motor reflexes (e.g., deep tendon reflexes, superficial abdominal reflexes, triple flexion withdrawal of lower extremities, and the Lazarus sign —complex spinal reflex flexion of the arms and torso upon neck flexion or hypoxic stimulus) originate within the isolated spinal cord and do NOT preclude or invalidate the diagnosis of brain death .
3. The Apnea Test Protocol
The apnea test confirms the complete absence of spontaneous respiratory drive when the medullary respiratory center is subjected to maximum hypercapnic stimulation.
Prerequisites: Core temperature above the national threshold (for example ≥ 36 °C \ge 36\text{°C} ≥ 36 °C under World Brain Death Project and US criteria), systolic blood pressure ≥ 100 mmHg \ge 100\text{ mmHg} ≥ 100 mmHg , normovolemia, baseline normocapnia ( P a CO 2 35 − 45 mmHg P_a\text{CO}_2\text{ }35-45\text{ mmHg} P a CO 2 35 − 45 mmHg ), and pre-oxygenation with 1.0 F i O 2 1.0\text{ }F_i\text{O}_2 1.0 F i O 2 for 10 − 15 minutes 10-15\text{ minutes} 10 − 15 minutes to achieve a P a O 2 ≥ 200 mmHg P_a\text{O}_2 \ge 200\text{ mmHg} P a O 2 ≥ 200 mmHg .
Procedure: Disconnect the patient from the mechanical ventilator. Deliver continuous insufflation of 100 % O 2 100\%\text{ O}_2 100% O 2 at 6 L/min 6\text{ L/min} 6 L/min via a catheter positioned at the level of the carina (or use a CPAP valve circuit with PEEP 5 cm H 2 O 5\text{ cm}\text{H}_2\text{O} 5 cm H 2 O to prevent derecruitment). Observe the chest and abdomen continuously for 8 to 10 minutes 8\text{ to }10\text{ minutes} 8 to 10 minutes for any spontaneous respiratory effort. At 100 % 100\% 100% oxygenation, P a CO 2 P_a\text{CO}_2 P a CO 2 rises at approximately 2 − 3 mmHg/minute 2-3\text{ mmHg/minute} 2 − 3 mmHg/minute .
Confirmation of Brain Death (Positive Test):
Complete absence of spontaneous respiratory effort (no breathing, no gasping);
Post-test arterial blood gas reaches the hypercapnic target: P a CO 2 ≥ 60 mmHg P_a\text{CO}_2 \ge 60\text{ mmHg} P a CO 2 ≥ 60 mmHg with p H < 7.30 pH < 7.30 p H < 7.30 (World Brain Death Project 2020); the 2023 US guideline requires P a CO 2 ≥ 60 mmHg P_a\text{CO}_2 \ge 60\text{ mmHg} P a CO 2 ≥ 60 mmHg and a rise of ≥ 20 mmHg \ge 20\text{ mmHg} ≥ 20 mmHg above baseline, with p H ≤ 7.30 pH \le 7.30 p H ≤ 7.30 ;
The UK code instead starts from P a CO 2 > 6.0 kPa P_a\text{CO}_2 > 6.0\text{ kPa} P a CO 2 > 6.0 kPa with p H < 7.40 pH < 7.40 p H < 7.40 and requires a rise of > 0.5 kPa > 0.5\text{ kPa} > 0.5 kPa during 5 minutes of apnoea. Always apply the national criteria in force.
Criteria to Abort Test: If severe arterial hypotension ( SBP < 90 mmHg \text{SBP} < 90\text{ mmHg} SBP < 90 mmHg ), significant arterial desaturation ( S p O 2 < 85 % S_p\text{O}_2 < 85\% S p O 2 < 85% ), or malignant cardiac dysrhythmias develop, immediately draw an arterial blood gas, reconnect the ventilator with 100 % O 2 100\%\text{ O}_2 100% O 2 , and abort the test. If the blood gas does not fulfill the P a CO 2 P_a\text{CO}_2 P a CO 2 threshold, the test is deemed inconclusive and an ancillary test must be performed.
4. Ancillary (Confirmatory) Tests
Ancillary tests are not mandatory in typical clinical examinations, but are legally and medically required when:
The clinical examination cannot be completed (e.g., severe facial trauma precluding cranial nerve assessment, cervical spine trauma);
The apnea test cannot be safely completed or tolerated due to severe hemodynamic collapse or refractory hypoxemia;
Significant metabolic or pharmacological confounders (e.g., barbiturate therapy) cannot be cleared.
Ancillary Test Diagnostic Principle Brain Death Confirmatory Finding
Four-Vessel Cerebral Angiography Gold standard; evaluates intracranial arterial blood flow under pressure Complete absence of intracranial blood flow beyond the carotid siphon (internal carotid arteries) and foramen magnum (vertebral arteries).
Transcranial Doppler (TCD) Insonation of middle cerebral and basilar arteries Bilateral reverberating / oscillating flow (biphasic systolic forward flow and diastolic retrograde flow) or small systolic spikes ( < 20 cm/s <20\text{ cm/s} < 20 cm/s ) with complete absence of diastolic flow.
Radionuclide Scintigraphy / SPECT Injection of 99 m Tc ^{99\text{m}}\text{Tc} 99 m Tc -HMPAO or 99 m Tc ^{99\text{m}}\text{Tc} 99 m Tc -ECD tracer Complete absence of intracranial tracer uptake ( "empty lightbulb sign" ), with preserved extracranial scalp and facial perfusion ( "hot nose sign" ).
Electroencephalography (EEG) Records spontaneous cortical electrical activity Electrocerebral inactivity (isoelectric / flat EEG) with no electrical activity > 2 μ V >2\text{ }\mu\text{V} > 2 μ V for at least 30 minutes 30\text{ minutes} 30 minutes at high sensitivity ( 2 μ V/mm 2\text{ }\mu\text{V/mm} 2 μ V/mm ).
Clinical Pearls and Exam Traps
The Lazarus Sign Trap: Spinal cord reflexes can mimic voluntary or involuntary movement. Movements such as triple flexion, deep tendon reflexes, and the Lazarus sign (spontaneous arm flexion across the chest upon apnea stimulation) originate in the spinal cord, which receives blood supply from segmental spinal arteries. They do not indicate brainstem activity and do not rule out brain death.
PRIS Warning Signs: In patients receiving propofol, unexplained widening anion gap metabolic acidosis, hyperkalemia, or new right bundle branch block/Brugada-like ST elevations are critical warning signs of Propofol Infusion Syndrome (PRIS). The infusion must be discontinued immediately.
Temperature Rule in Brain Death: At a core temperature of 34 °C 34\text{°C} 34 °C , testing cannot proceed under World Brain Death Project or US criteria, which require ≥ 36 °C \ge 36\text{°C} ≥ 36 °C (the UK code requires > 34 °C > 34\text{°C} > 34 °C ). Rewarm the patient to the applicable threshold before cranial nerve or apnea testing.